January 25, 2023
James Phelps
For the treatment of major depression, electroconvulsive therapy (ECT) is markedly more effective than ketamine, per this meta-analysis of 6 randomized head-to-head comparison studies, at the end of 3–4 weeks of treatment. In 2 of these studies that measured longer-term outcomes (i.e., 2 and 10 months after treatment, respectively), no difference was found in ketamine vs ECT.
Pharmaceuticals
January 24, 2023
Adam Włodarczyk, Alicja Dywel, Wiesław Jerzy Cubała
10 citations
There is evidence for ketamine use in treatment-resistant depression (TRD). Several safety concerns arise regarding adverse drug reactions in specific subpopulations. The aim of this study was to investigate the safety of intravenous ketamine treatment in relation to dissociative and psychotic measures in TRD inpatients with Major Depressive Disorder (MDD) and Bipolar depression (BP) with...
CNS Drugs
January 22, 2023
Jules S Mitchell, Daniel Francis Hermens, Maxwell R. Bennett et al.
15 citations
Anorexia nervosa is a disorder associated with serious adverse health outcomes, for which there is currently considerable treatment ineffectiveness. Characterised by restrictive eating behaviours, distorted body image perceptions and excessive physical activity, there is growing recognition anorexia nervosa is associated with underlying dysfunction in excitatory and inhibitory neurometabolite...
Pharmacoeconomics
January 20, 2023
Carla Rognoni, Camilla Falivena, Francesco Costa et al.
Aim: Major depressive disorder is considered one of the most frequent diseases in the general population, and treatment-resistant depression (TRD) represents the subset with more significant clinical and social impact. Large, robust phase III studies have shown safety and efficacy of esketamine nasal spray plus SSRI/SNRI antidepressants (ADs) compared with SSRI/SNRI plus placebo nasal spray in...
Molecular Psychiatry
January 20, 2023
Jie Guo, Di Qiu, Han-Wen Gu et al.
46 citations
Ketamine, a commonly used general anesthetic, can produce rapid and sustained antidepressant effect. However, the efficacy and safety of the perioperative application of ketamine on postoperative depression remains uncertain. We performed a meta-analysis to determine the effect of perioperative intravenous administration of ketamine on postoperative depression. Randomized controlled trials...
International Journal of Molecular Sciences
January 18, 2023
Moritz Haaf, Stjepan Curic, Jonas Rauh et al.
9 citations
NMDA-receptor hypofunction is increasingly considered to be an important pathomechanism in schizophrenia. However, to date, it has not been possible to identify patients with relevant NMDA-receptor hypofunction who would respond to glutamatergic treatments. Preclinical models, such as the ketamine model, could help identify biomarkers related to NMDA-receptor function that respond to...
The World Journal of Biological Psychiatry
January 18, 2023
Shakila Meshkat, Sipan Haikazian, Joshua D. Di Vincenzo et al.
61 citations
Abstract Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be used to treat major depressive disorder by single or repeated infusions. However, the accessibility and scalability of oral ketamine make it preferred over intravenous ketamine. In this systematic review, we aim to evaluate the efficacy, tolerability, and safety of oral ketamine, esketamine and...
International Journal of Research in Medical Sciences
January 17, 2023
Ubaid Rasool, Neelofer Jan, Marya Zahoor et al.
3 citations
Background: Treatment resistant depression can be a life-threatening condition as it leads to an increase of suicide attempts by two to three folds. It has been estimated that nearly 1 million people die due to suicide every year, and more than two-third of these cases occur when the person is undergoing a major depressive episode. Ketamine is an NMDA receptor antagonist, an anesthetic agent...
medRxiv
January 17, 2023
Ryan Yermus, Michael Verbora, Sidney H. Kennedy et al.
2 citations
preprint
Abstract IMPORTANCE Ketamine-Assisted Psychotherapy (KAP) is an emerging treatment option to alleviate treatment resistant affective disorders, but its long term effectiveness remains unclear. OBJECTIVE To examine the treatment effects of KAP on anxiety, depression, and post traumatic stress disorder (PTSD) at 1, 3, and 6 months post treatment. DESIGN, SETTING, AND PARTICIPANTS This...
bioRxiv
January 16, 2023
Anastasiya Zaytseva, Evelina Bouckova, McKennon J. Wiles et al.
preprint
Ketamine is shown to enhance excitatory synaptic drive in the hippocampus, which is presumed to underlie its rapid antidepressant effects. Moreover, ketamine’s therapeutic actions are likely mediated by enhancing neuronal Ca2+ signaling. However, ketamine is a noncompetitive NMDA receptor (NMDAR) antagonist that inhibits excitatory synaptic transmission and postsynaptic Ca2+ signaling. Thus, it...